Latest From Bioprojet
Mithra says its new oral contraceptive could be a major breakthrough in a “space where there hasn’t been any innovation in decades."
A US Complete Response Letter for SPARC’s paclitaxel product has cast a cloud over the project’s viability, but the company is still hopeful of an FDA approval by the fourth quarter of fiscal 2021. With the delay in commercialization, investment in some prioritized projects might also require external funding or even an exit from other research assets.
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Senior Management
- Jeanne-Marie Lecomte, MD, Chmn. & Managing Dir.
- Contact Info
Phone: (33) 47 03 66 33
30, rue des Francs-Bourgeois